Clusterin: A Biomarker for Alzheimer Disease?
Clusterin: A Biomarker for Alzheimer Disease?
This is the Medscape Neurology Minute. I'm Dr. Alan Jacobs. Researchers from The Netherlands have published a case cohort study nested within the Rotterdam study evaluating the potential of plasma clusterin as a biomarker of the presence, severity, and risk for Alzheimer disease (AD). Plasma levels of clusterin were measured at baseline in 60 individuals with prevalent AD, a random subcohort of 926 participants, and in an additional 156 participants who were diagnosed with AD during follow-up until January 2007. The main outcome measures were prevalent AD, severity of AD measurement by the Mini-Mental State Examination score, and the risk of AD developing during follow-up. The likelihood of prevalent AD increased with increasing plasma levels of clusterin. Among patients with AD, higher clusterin levels were associated with more severe disease. Plasma clusterin levels were not related to the risk for incident AD during the total follow-up or within 3 years of baseline [examination]. The investigators concluded that plasma clusterin levels were signficantly associated with the baseline prevalence and severity of AD but not with the incidence of AD. This article was selected from Medscape Best Evidence. I'm Dr. Alan Jacobs.
Abstract
This is the Medscape Neurology Minute. I'm Dr. Alan Jacobs. Researchers from The Netherlands have published a case cohort study nested within the Rotterdam study evaluating the potential of plasma clusterin as a biomarker of the presence, severity, and risk for Alzheimer disease (AD). Plasma levels of clusterin were measured at baseline in 60 individuals with prevalent AD, a random subcohort of 926 participants, and in an additional 156 participants who were diagnosed with AD during follow-up until January 2007. The main outcome measures were prevalent AD, severity of AD measurement by the Mini-Mental State Examination score, and the risk of AD developing during follow-up. The likelihood of prevalent AD increased with increasing plasma levels of clusterin. Among patients with AD, higher clusterin levels were associated with more severe disease. Plasma clusterin levels were not related to the risk for incident AD during the total follow-up or within 3 years of baseline [examination]. The investigators concluded that plasma clusterin levels were signficantly associated with the baseline prevalence and severity of AD but not with the incidence of AD. This article was selected from Medscape Best Evidence. I'm Dr. Alan Jacobs.
Abstract
Source...